WeiFu: A Novel Pan-Cancer Driver Gene Identification Method Using Incidence-Weighted Mutation Scores
Genetic and genomic variations are primary drivers of tumor development. Identifying driver genes from numerous passenger genes across pan-cancer poses a significant challenge due to varying mutation loads. While independent studies have elucidated cancer-associated mutation patterns within speci...
Saved in:
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
IEEE
2024
|
Subjects: | |
Online Access: | http://ir.unimas.my/id/eprint/47093/1/WeiFu_A_Novel_Pan-Cancer_Driver_Gene_Identification_Method_Using_Incidence-Weighted_Mutation_Scores.pdf http://ir.unimas.my/id/eprint/47093/ https://ieeexplore.ieee.org/document/10807179?denied= |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Genetic and genomic variations are primary drivers of tumor development. Identifying driver
genes from numerous passenger genes across pan-cancer poses a significant challenge due to varying
mutation loads. While independent studies have elucidated cancer-associated mutation patterns within
specific cancer types, a systematic approach to integrating these mutation data for assessing the impact of
gene mutations has been lacking. This study addresses this gap by integrating pan-cancer genomic somatic
mutation data and introducing a novel mutation weight fusion (WeiFu) score calculation method. WeiFu
computes frequency and weighted fusion scores by cancer type, facilitating the identification of potential
driver genes. Evaluation results on an integrated pan-cancer dataset comprising 29 different cancer types
demonstrate that WeiFu significantly outperforms current well-known approaches in prediction accuracy,
sensitivity, and specificity. Notably, WeiFu recovers 277 known cancer genes among the top 500 ranked
candidates and successfully identifies potential driver genes supported by strong evidence. Consequently,
WeiFu shows considerable promise for identifying driver genes within the rapidly expanding corpus of cancer
genomic data. |
---|